Heterologous ChAdOx1-S/BNT162b2 Vaccination - Infinity Accéder directement au contenu
Article Dans Une Revue Clinical Infectious Diseases Année : 2022

Heterologous ChAdOx1-S/BNT162b2 Vaccination

Résumé

Dear Editor, A recent report questioned whether one vaccine was better than another and how to evaluate this difference, but only homologous vaccination schedules were considered. Concern about the safety of the ChAdOx1-S vaccine have prompted some European countries to recommend using a heterologous booster, as proposed for mRNA vaccines for people under 55 years old . Immunogenicity and reactogenicity of a BNT162b2 booster in ChAdOx1-S-primed subjects was assessed in a multicenter, open-label, randomised, controled phase 2 trial, but included no homologous vaccination comparator. Few studies have compared the immune responses to homologous and heterologous vaccination schedules in humans.

Dates et versions

hal-03682415 , version 1 (31-05-2022)

Identifiants

Citer

Chloé Dimeglio, Fabrice Herin, Isabelle Da-Silva, Isabelle Jougla, Claire Pradere, et al.. Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, 2022, 74 (7), pp.1315-1316. ⟨10.1093/cid/ciab705⟩. ⟨hal-03682415⟩
27 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More